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Abstract 
 
Adipocytes take up long chain fatty acids through diffusion and through a low 
capacity protein mediated transport system on the plasma membrane, whereas 
fatty acid efflux is considered to occur by diffusion. Although studies have 
revealed the importance of fatty acid transport proteins (FATPs), long chain acyl 
coenzyme A synthetases (ACSLs) and fatty acid translocase (FAT, also known 
as CD36) in fatty acid uptake, other membrane proteins could be involved, and 
no membrane proteins have been associated with fatty acid efflux. To identify 
potential membrane proteins that are involved in regulating fatty acid flux in 
adipocytes, the expression levels of 55 membrane transporters without known 
function were screened in subcutaneous adipose samples from obese patients 
before and after bariatric surgery using branched DNA methodology. Among 
the 33 solute carrier (SLC) transporter family members screened, the 
expression of 14 members showed significant changes before and after 
bariatric surgery. One of them, Slc43a3, increased about 2.5-fold after bariatric 
surgery. The expression levels of Slc43a3 in various mouse adipose depots 
and during adipocyte differentiation were explored in C57Bl6J mice and OP9 
murine adipocyte cells. The functional significance of Slc43a3 in regulating fatty 
acid transport was studied using overexpression or silencing of Slc43a3 in 
differentiated OP9 cells. Slc43a3 is highly expressed in adipose tissue and 
induced during adipocyte differentiation in OP9 cells. Knockdown of Slc43a3 
with siRNA in differentiated OP9 adipocytes reduced both basal and forskolin-
stimulated fatty acid efflux. Interestingly, knockdown of Slc43a3 with siRNA in 
differentiated OP9 adipocytes also increased fatty acid uptake and lipid droplet 
accumulation. In contrast, overexpression of Slc43a3 decreased fatty acid 
uptake in differentiated OP9 cells and resulted in decreased lipid droplet 
accumulation. Therefore, Slc43a3 seems to regulate fatty acid flux in 
adipocytes, functioning as a positive regulator of fatty acid efflux and as a 
negative regulator of fatty acid uptake. 
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1 Introduction 
 
1.1 Functions of fatty acids 
In general, fatty acids (FAs) have a negative connotation since they are known 
to be related not only to cardiovascular disease, but also to influence metabolic 
diseases such as type 2 diabetes, inflammatory diseases and cancer (1). 
Nevertheless, FAs play important roles in a variety of cellular functions, such as 
the production and storage of energy, synthesis of phospholipids, glycolipids, 
and cellular signaling messengers, modification of proteins for targeting to 
cellular membranes, and regulation of gene expression (2–4). 
FAs are built of hydrocarbon chains, which may differ in length as well as in 
their degree of unsaturation. They are composed of a methyl group on one and 
a carboxyl group on the other end. FAs are considered saturated, if there are 
only single bonds between neigboring carbons in the hydrocarbon chain. 
Unsaturated FAs have carbon-carbon double bonds and can be further 
classified in monounsaturated (only one double bond) and polyunsaturated FAs 
(multiple double bonds) (5).  
FAs are stored as triacylglycerols (TAG), a chemical compound derived from 
glycerol and three fatty acids, in adipocytes during energy abundance and 
released into the plasma during times of energy need (6). While stored in 
adipocytes, FAs are an important source of thermal and electrical insulation, as 
well as protection against mechanical compression. Since “a gram of nearly 
anhydrous fat stores more than six times as much energy as a gram of hydrated 
glycogen” it is not surprising that “TAG rather than glycogen were selected in 
evolution as the major energy reservoir” (2). In order to function as an energy 
source, FAs are released from TAG and degraded to FAs and glycerol, which 
are released from the adipose tissue and carried to energy-requiring tissues. To 
make sure that the FAs reach their assigned tissue, they are bound to one of 
the following five lipoproteins: chylomicrons, very low density lipoproteins 
(VLDL), intermediate density lipoproteins (IDL), low density lipoproteins (LDL) or 
HDL high density lipoproteins (HDL). This form of transport also assures that 
the hydrophobe lipids are not precipitating in the blood. The lipoproteins consist 
of a core of hydrophobe lipids which is surrounded by a coat of more hydrophile 
lipids and proteins (the so-called apolipoproteins). The demanding cell must 
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then “free” the FAs from their transport vehicles. This step is mainly performed 
by the hormone-sensitive lipase (HSL) which gradually separates the FAs from 
the glycerol by hydrolysis. For further processing the FAs are being activated 
and then transported into mitochondria for degredation. In the mitochondria the 
FAs are broken down into acetyl-CoA, which then will be fed into the citric acid 
cycle for energy production (2). 
Another main task of FAs is the composition of the plasma membrane (PM). 
The PM surrounds the cytoplasm and therefore seperates the inside of the cell 
from its environment. It consists of a lipid bilayer, allowing the cell to control the 
extent of communication and exchange of substances between the intracellular 
and extracellular space. It is built of various biological molecules, especially 
lipids and proteins. With an amount of more than 50%, phospholipids (typically 
composed of two FAs and a hydrophilic head comprised of a phosphate group) 
are the major component of the PM. Glycolipids (lipids containing sugar) 
account for 5-10% of lipid in the PM and are vital for intracellular 
communication. 
FAs are both: modulators and messengers in signal transduction. They are 
particulary involved in the communication at the level of the PM. FAs activate 
and/or inhibit enzymes and proteins of the cyclic adenosine monophosphate 
(cAMP) and the protein kinase C signalling pathways as well as those involved 
in ion fluxes and mobilization (7). As “secondary messengers” lipid molecules 
(especially in form of arachidonic acids) can bind to intracellular enzymes and 
function as an arbitrator between the extra- and intracellular space.  
The modification of proteins by attachment of FAs occurs on many proteins of 
various structure and function. The two most common types of fatty acylation of 
proteins are modifications with myristate (14-carbon saturated FA) and 
palmitate (16-carbon saturated FA). Whereas the major function of myristate is 
to help in guiding the modified protein to the PM, palmitate serves as an 
important driving force for proteins to connect with lipid rafts (specialized 
membrane microdomains) (8,9). 
One of the other key functions of FAs is the regulation of the expression of 
genes involved in lipid and energy metabolism, cellular proliferation and 
apoptosis. Polyunsaturated FAs for example reduce the expression of genes 
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involved in FA and cholesterol synthesis (10). 
 
1.2. Transport of fatty acids across the plasma membrane 
Most cells, with the exception of adipocytes, have a very limited capacity for 
storing FAs, in the form of triglycerides (or for de novo synthesis of FA), 
therefore circulating plasma FAs are the most important source of FA for most 
tissues (11). Short and medium chain FAs have high PM permeability and can 
diffuse freely and easily through the PM of cells. Long chain FAs (LCFAs), 
however, have much lower water solubility. Hence LCFAs are bound to albumin 
extracellularly and to fatty-acid-binding-protein (FABP) intracellularly in order to 
be buffered for their extremely low aqueous concentration (12). The transport of 
FAs into and out of adipocytes is controlled by a complex series of proteins and 
enzymes and influenced by a variety of metabolic and hormonal factors (6).  
 
1.2.1 Fatty acid uptake  
Different rates of FA uptake are observed among various cell types, with 
metabolically active cells having increased rates of FA uptake (13). The rates of 
cellular FA uptake are also regulated acutely and chronically by hormones 
(such as insulin) and metabolic status (in case of obesity) (14,15). 
The uptake of LCFAs involves multiple steps. First, the LCFA is separated from 
serum albumin, before diffusing through the outer aqueous phase. After an 
attachment of the LCFA to the outer leaflet of the PM, a translocation or flip-flop 
from the outer to the inner leaflet occurs. The LCFA then gets released from the 
inner leaflet into the inner aqueous phase. The predominantly discussed step of 
this process is the fatty acid translocation and the question if it is diffusion- or 
protein-mediated (6). In addition to the bidirectional flip-flop model for 
transporting FAs across the plasma membrane, studies have demonstrated the 
importance of specific LCFA transport systems in metabolically active tissues, 
such as intestine, heart, adipose tissue, and the liver (16). This transport 
appears to involve membrane proteins that can mediate FA uptake via a rapid, 
saturable, substrate specific and hormonally related mechanism.  
In the heart, the use of the main metabolic substrates: glucose and LCFA is not 
only regulated by substrate availability and competition at the level of 
mitochondria (Randle-cycle), but also at the site of cellular entry. CD36 is 
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responsible for the majority of LCFA uptake into the cardiomyocyte. CD36 is an 
integral membrane protein and belongs to a family of class B scavenger 
receptors. Moreover, CD36 is thought to bind many ligands like collagen, 
thrombospondin, sickle cell erythrocytes, oxidized low-density lipoproteins and 
apoptotic cells (6). Nowadays, CD36 is known to be the main protein involved in 
FA transport into adipocytes, enterocytes and cardiac/skeletal myocytes (17). In 
the heart, the translocation of CD36 from intracellular compartments to the 
sarcolemma (PM of a striated muscle fiber cell), has been found to be 
responsible for stimulus-induced LCFA uptake. High contractile activity and 
circulating insulin are the two leading stimuli responsible for an acute increase 
in cardiac substrate uptake (18). Whereas conditions such as obesity and 
diabetes are chronically regulating the LCFA uptake (15). 
In adipocytes, permeation of LCFAs across the plasma membrane relies on a 
high affinity, low capacity protein facilitated transport system. Studies have 
shown the significance of several different proteins, such as FATPs (in 
adipocytes predominantly FATP1), ACSLs and CD36, in the protein-facilitated 
process of FA transport. 
Fatty acid transport proteins (FATPs, SLC27A1-6) facilitate the transport of 
LCFAs across the PM and intracellular membranes. They are a group of six 
related integral membrane proteins that are expressed in all cells with high 
levels of FA uptake and active lipid metabolism. The mRNA expression and/or 
protein levels of FATPs are regulated by hormones, inflammatory mediators, 
such as endotoxin, tumor necrosis factor alpha (TNFα), interleukin-1 (IL-1) and 
by activators of the peroxisome proliferator activated receptor (PPAR) alpha or 
gamma (19). 
Long chain acyl coenzyme A synthetases (ACSLs) are enzymes of the ligase 
family that activate the breakdown of complex FAs, by catalyzing the formation 
of fatty acyl-CoA, so they can enter their designated metabolic pathway. ACSLs 
consist of five different isoenzymes, each in charge of different tasks regarding 
their expression in particular tissues. Besides being linked to various diseases 
(fatty liver disease, atherosclerosis, obesity and diabetes), they also regulate 
apoptosis and cell proliferation through special mechanisms (20,21). 
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Even though there are numerous studies and discussions on how FAs traverse 
the PM to enter the soluble cytoplasm, the exact mechanisms are not yet fully 
understood (22). Specifically, there is a debate on the rate-limiting step in the 
overall process of FA uptake and if, and to what extent, one or more 
membrane-associated proteins could facilitate and/or regulate FA uptake. 
 
 
 
Figure 1. Schematic representation of the current view of FA transport across 
the cell membrane. 
Because the exact mechanism of transmembrane translocation of FAs is still 
unknown, different models have been suggested. (1) In view of their 
hydrophobic nature, FAs could cross the membrane by simple diffusion. (2) 
Alternatively, CD36 (88 kDa; also referred to as ‘fatty acid translocase’), alone 
or together with the peripheral membrane protein FABPpm (plasma membrane-
associated fatty-acid-binding-protein; 43 kDa) accepts FAs at the cell surface to 
increase their local concentration and thus increase the number of fatty acid 
diffusion events. (3) It is also possible that CD36 itself actively transports fatty 
acids across the membrane. Once at the inner side of the membrane fatty acids 
are bound by cytoplasmic FABP (FABPc) before entering metabolic or 
signalling pathways. (4) Additionally, a minority of FAs are thought to be 
transported by fatty acid transport proteins and rapidly activated by plasma 
membrane acyl-CoA synthetase (ACS1) to form acyl-CoA esters. (5) Very-long-
chain FAs (>C22) are preferentially transported by FATPs and by action of their 
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synthetase activity directly converted into very-long-chain acyl-CoA esters 
(uptake by vectorial acylation). 
Figure 1 (and the associated explanation) are used with permission from 
Schwenk et al. “Fatty acid transport across the cell membrane: Regulation by 
fatty acid transporters” (12). 
 
1.2.2 Fatty acid efflux 
Although current studies oppose the idea that FA uptake is diffusion-mediated, 
FA efflux is still thought to occur by diffusion, without any proteins being 
associated with facilitating the process. In contradistinction to this hypothesis, 
Henkin et al. reported evidence that suggests the possibility of the involvement 
of proteins in FA efflux. Henkin et al. developed different assays and a special 
cell line to quantify FA efflux to generate evidence suggesting that adipocytes 
express an as yet unidentified FA transporter.  
In the search for these FA efflux mediating proteins the major FA uptake 
proteins (FATP, ACSL, CD36) were examined. Since flip-flop transport of FAs 
across the PM is bidirectional by nature, this mode could have also been true 
for protein-mediated transport. However, there is hardly any evidence that 
FATP, ACSL or CD36 are acting bidirectionally. FATP1 can be ruled out as a 
FA exporter since previous studies have shown that knockdown of FATP1 
results in a decrease of FA uptake and shows no effect on FA efflux (23). In 
CD36 knockout animals no obvious deficiencies in FA release from adipocytes 
can be observed (24). Febbraio et al. could even demonstrate that the FA 
serum levels in CD36 KO animals are actually elevated (25). ACSLs are also 
not probable candidates for FA exporters since by trapping FAs via activiation to 
acyl-CoA, they are acting undirectionally (24).  
Considering this situation, it is necessary to further explore the mechanisms and 
proteins involved in FA transport, especially the ones that could mediate FA 
efflux. The description of such a mechanism will not only help to understand an 
important pathway but could also have an important impact on the treatment of 
obesity-related diseases which are characterized by malfunctioning lipid 
transport (24).  
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1.3 Changes in fatty acid metabolism after bariatric surgery 
Bariatric Surgery is the most effective treatment of obesity and obesity-related 
disorders. Obese patients who have been unable to lose weight by non-surgical 
means profit from this intervention, because it reduces the risk for 
cardiovascular disease and others. The ultimate benefit of weight reduction 
comes with the reduction of the co-morbidities, quality of life and all-cause 
mortality (26). These co-morbidities include, among many others, hypertension, 
type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), 
inflammation and obstructive sleep apnea. While pharmaceutical treatments 
and lifestyle changes show only minor effects, bariatric surgery significantly 
reduces body weight and insulin sensitivity. Whereas in former days these 
effects were only attributed to malabsorption and restriction, it is now presumed 
that modifications in the anatomy of the gastrointestinal (GI) tract have an 
important effect on GI physiology, including changes in GI hormone secretion, 
which are necessary for regulating the feeding and energy metabolism. After 
bariatric surgery an increase of FFA outflow in the circulation can be observed. 
Due to a major deficiency of calories the body switches to fatty acid oxidation. 
The reesterfication of FFAs is reported to increase as much as sixfold during 
fasting (27). That’s why it’s not surprising that various studies demonstrate, that 
the FFA levels are elevated in the first few months after bariatric surgery 
(28,29). These changes in lipid homeostasis make pre- vs. post-bariatric 
surgery metabolism a great model for studying alterations in lipid flux.  
 
  
 8 
 
2 Aim of this study and research strategy 
 
2.1 Aim of this study 
Studies have demonstrated the importance of several different proteins, such 
as FATPs, ACSLs and CD36, in the protein-faciliated process of FA transport. 
Nevertheless, the precise mechanisms how FAs cross the PM to enter the 
soluble cytoplasm are not yet fully understood. Especially, the impact of one or 
more membrane-associated proteins on the rate-limiting step in the global 
process of FA uptake is still being discussed. In contradistinction, FA efflux from 
adipocytes is attributed to diffusion, which does not involve any proteins 
facilitating the process, though Henkin et al. previously reported evidence to 
suggest the opposite; the possibility of a protein-mediated transport across the 
PM. 
The aim of this study is to find possible candidates for these mechanisms. It will 
be investigated if particular proteins, which are involved in FA efflux, exist and if 
special membrane-associated proteins can be shown to regulate the rate of FA 
uptake.  
 
2.2 Research strategy/approach 
To find potential candidates for these mechanisms an in-silico study of all 
transporter genes fulfilling the following criteria: unknown function, plasma 
membrane location and significant expression in adipose tissue, will be 
performed. One of the transporter gene families that comes into focus is the 
family of the ATP-binding cassette (ABC) transporters, of which almost half are 
thought to facilitate the ATP-dependent translocation of lipids or lipid-related 
compounds (30–32). Another family of potentially relevant membrane transport 
proteins is the family of the Solute Carriers (SLC), with over 400 members, most 
of which are located in the cell membrane (33–36).  
The mRNA expression levels of gene candidates from the in-silico study in 
patients before and after bariatric surgery will be examined. Bariatric surgery 
will therefore be used as model for a physiological change in FA flux. If the 
mRNA expression level of the selected gene candidates increases by more 
than 1.5-fold pre- vs. post-op, they will be further analyzed in epicutaneous, 
subcutaneous and brown adipose tissue as well as in liver tissue. Genes that 
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express highly in these tissues will be studied in OP9 murine adipocyte cells 
and primary preadipocytes throughout differentiation. The ones that show 
significant changes during adipocyte differentiation in OP9 cells and primary 
preadipocytes will be further investigated. It will be analyzed if the 
knockdown/overexpression of one of the identified genes from the in-silico 
study will have a significant effect on FA uptake and/or FA efflux. Furthermore, 
a possible interaction between newly identified transporter proteins and already 
existing ones, such as CD36, will be explored.  
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3 Material and Methods 
 
3.1 Chemicals and reagents 
Reagents were obtained from the following sources: cAMP Complete ELISA kit 
from Enzo Life Sciences, Farmingdale, NY, USA; Non-esterified fatty acid HR 
Series NEFA-HR(2)  from Wako Diagnostics, Wako Life Sciences, Inc., 
Mountain View, CA, USA; QBT Fatty Acid Uptake Assay Kit from Molecular 
Devices Corporation, Sunnyvale, CA, USA; All other chemicals were from 
Sigma-Aldrich, St. Louis, MO. 
 
3.2 Animals 
Wildtype C57Bl6/J and CD36 knockout (KO) mice were obtained from the 
Jackson Laboratory (Bar Harbor, ME) and were used for the collection of liver 
and fat tissues. Mice were housed in the animal facility at the VA Palo Alto 
Health Care System on a 12/12 h light/dark cycle. All procedures were in 
accordance with institution guidelines and approved by the Institutional Animal 
Care and Use Committee of the VA Palo Alto Health Care System. 
 
3.3 Patient sample collection and RNA preparation 
Patients undergoing an elective VSG (vertical sleeve gastrectomy) procedure 
were recruited and informed consent was obtained from each study participant. 
Inclusion criteria included men and women older than 21 years of age with a 
body mass index (BMI) ≥35.0 kg/m2, and meeting criteria by American Diabetes 
Association standards for pre-diabetes or type 2 diabetes mellitus (T2DM). For 
laparoscopic VSG surgery, a 4.8mm stapler load was used to divide the greater 
curvature of the stomach 5cm from the pylorus and remaining 3cm from the 
angularis incisura. 3.5mm stapler loads were fired thereafter progressing up to 
the angle of His to complete the VSG. Details of the surgical procedures have 
been described by Jahansouz et al. (37). Demographic data on sex, age, and 
T2DM were collected for obese patients at the time of surgery and seven days 
following bariatric surgery. Weight and height were measured immediately prior 
to surgery (pre-op) and during the postoperative visit. BMI was calculated as 
weight (kg) divided by height (m2). Additional details as to the molecular 
changes occurring following bariatric surgery have been published by 
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Jahansouz et al. (38). The University of Minnesota and St. Cloud Hospital 
Institutional Review Boards approved all investigations and informed consent 
was obtained from each participant. Abdominal subcutaneous adipose tissue 
biopsies from patients were processed for tissue analysis. Approximately 2-3g 
of fat was obtained from each subject and immediately frozen with liquid 
nitrogen and stored at -80°C until analyzed. For RNA preparation, 
approximately 0.3g of adipose tissue was extracted using TRIzol© (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions. 
QuantiGene2.0 RNA assays for RNA level analysis: RNA levels were assayed 
using QuantiGene2.0 RNA assays from Affymetrix, which are hybridization-
based assays that utilize a branched DNA technology for signal amplification for 
the direct quantitation of gene expression transcripts. The QuantiGene Plex 
assay combines branched DNA (bDNA) signal amplification with Luminex multi-
analyte profiling bead (xMAP®) technology to enable the capture and 
quantitation of multiple RNA targets simultaneously. First, samples are lysed to 
release the target RNA. Second, the lysates are incubated overnight with an 
oligonucleotide probe set and color-coded bead mix. During this incubation, the 
probes cooperatively hybridize to both the target RNA and the capture probes 
conjugated to the microspheres, capturing the target RNA onto designated 
beads. Third, signal amplification is achieved through sequential hybridizations 
of the bDNA pre-amplifier, amplifier, and biotinylated label probe molecules to 
the target. Finally, addition of streptavidin-phycoerythrin generates a fluorescent 
signal that is proportional to the amount of target RNA captured. Fluorescence 
intensity is measured using a Luminex instrument. This assay system provides 
a robust and accurate measurement utilizing xMAP Luminex beads for 
multiplexing RNA targets. We selected 22 members of the ABC transporter 
family and 33 members from the SLC family with unknown functions together 
with control genes (Supplemental Table S1) for analysis simultaneously on the 
Luminex® platform. 250ng total RNA for each sample was incubated overnight 
at 54°C with unique fluorescent beads which have target-specific capture 
extenders and label extenders. The beads are coated with capture probes 
specific to the capture extenders, thus cooperatively hybridizing each target 
gene to a unique bead. After overnight incubation, the bDNA signal 
amplification portion was initiated by first washing the beads, followed by a 
 12 
 
1-hour incubation with the preamplifier DNA mix at 50°C. The beads were next 
washed, followed by a 1-hour incubation with the amplifier DNA solution mix at 
50°C. Biotinylated DNA label probe was added to the wells and incubated at 
50°C for 1 hour (h). Finally, the beads were washed, followed by incubation at 
room temperature for 30 minutes (min) with streptavidin phycoerythrin. The 
beads were washed and read on the Luminex® instrument. 
 
3.4 Cell Cultures 
 
3.4.1 OP9 cells 
OP9 cells, a stromal cell line from mouse bone marrow (39) (obtained from 
ATCC), were grown to confluence in Dulbecco’s modified Eagle’s medium, 
containing 20% fetal bovine serum, 100U/ml penicillin and 100µg/ml 
streptomycin. Before RNA isolation, OP9 cells were treated with 0.5mM 
isobutyl-methylxanthine and 1µM dexamethasone on day 0 and with 1µg/ml 
insulin on day 2. Cells were harvested on day 0, day 3 (72 hours) and day 9 
(216 hours) for further experiments.  
 
3.4.2 Primary preadipocytes 
Primary preadipocytes were isolated by collection of white adipose tissue 
from wildtype C57Bl6/J mice. Fat pads were briefly washed with phosphate-
buffered saline (PBS) and minced quickly with small scissors into small pieces 
for ca. 5min. Collagenase buffer (10ml) was added to the minced fat pads from 
2 mice, which were then incubated at 37°C for 20min in small plastic cornical 
flasks. Fat cell wash buffer (5ml) was added to the flasks. The digested mix was 
passed through a nylon mesh and the tubes were centrifuged gently at 1500 
rounds per minute (rpm) for 3-4 min. The fat cells were floating on top, so the 
solution could easily be sucked out with long needles on top of 50ml syringes. 
The cells were washed with fat cell wash buffer 2-3 times, with gentle 
centrifugation in between to pack the cells, before being cultured in Dulbecco’s 
modified Eagle’s medium containing 10% fetal bovine serum, 100U/ml 
penicillin and 100µg/ml streptomycin. Before RNA isolation, primary 
preadipocytes were differentiated as described above and harvested on day 
0, day 7 and day 14.  
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Buffers for Collagenase 
A) Hepes Stock Solution 
1 – HEPES (Sigma H-3375) 24.0g 
2 – NaCl  7.0g 
3 – KCl 0.385g 
4 – CaCl2 0.147g 
5 – Glucose 0.9008g 
6 – Water  500ml 
B) Albumin Solution: 3g/100ml  
C) Equal parts of A (Hepes Stock) and B (Albumin Solution) were mixed and 
adjusted to a pH of 7.4. 
D) 100ml of Collagenase was weighed and then mixed with 100 ml of the A and 
B buffer mix, before being filtered with a sterile 0.45µm and then 0.22 µm 
syringe filter. 
 
 
3.5 Transfections 
The pEZ-M51-Slc43a3-His plasmid was purchased from GeneCopoeia 
(Rockville, MD) for overexpression and the Slc43a3 Silencer Pre-designed 
siRNAs were purchased from Ambion Life Technologies, Inc. (Austin, TX, USA) 
for knockdown of Slc43a3. Scrambled siRNA was purchased from Santa Cruz 
Biotechnology and used as a negative control. OP9 cells were used for 
transfection with Slc43a3 siRNA and scrambled siRNA. Cells were plated in 96-
well culture plates and transfection of siRNA or plasmid was performed with 
PolyJetTM reagent (SignaGen Laboratories, Gaithersburg, MD, USA) following 
a reverse transfection protocol. Cells were cultured at 37°C, 5% CO2 for 5h, 
then the medium was replaced with fresh medium containing 0.5mM isobutyl-
methylxanthine and 1µM dexamethasone and subsequently cultured according 
to the differentiation protocol. After 120h (5 days), the cells were used for FA 
efflux- and uptake assays, as well as cAMP assays. 
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3.5.1 Construction of Slc43a3 clone 
The plasmid pEZ-M51-Slc43a3-His was transformed into DH5alpha competent 
cells (engineered E. coli cells which maximize transformation efficiency).  
The DH5alpha cells were taken from the -80°C freezer and thawed on ice. The 
cells were gently mixed using the tip of a pipette and 35µl of cells were 
aliquoted into a 1.5ml tube. 1.5µl (= ca. 300ng) of Slc43a3 plasmid DNA was 
added to the cells and mixed gently. For the pUC19 (a commonly used cloning 
vector) control, 2.5µl (250pg) of DNA was added and mixed gently. The tubes 
were incubated on ice for 30min. The cells were shock heated for 20 seconds 
(s) in a 42°C water bath and afterwards placed on ice for 2min. A volume of 
500µl of pre-warmed lysogeny broth (LB) was added followed by an incubation 
for 1h at 225rpm. 200µl of the culture were spread on pre-warmed selective LB-
Ampicillin (LB+Amp) plates and incubated overnight at 37°C. A single colony 
was picked after 12-16h and grown in 200ml of LB+Amp media for another 12-
16h.  
 
 
 
Figure 2. Slc43a3 plasmid DNA from GeneCopoeia.  
(A) Vector information. (B) Restriction enzyme information.  
 
For the isolation of plasmid DNA from E. coli the QIAprep Spin Midiprep Kit was 
used. The overnight bacterial culture was harvested by centrifugation (6000 x g, 
15min, 4°C). The bacterial pellet was resuspended in 4ml of Buffer P1. 4ml of 
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Buffer P2 was added and mixed thoroughly by vigorously inverting the mix for 6 
times. The mixture was incubated at room temperature for 5min before 4ml of 
prechilled Buffer P3 was added and mixed by vigorously inverting the tubes 6 
times. The mix was incubated for 15min on ice, followed by centrifugation 
(20000 x g, 30min, 4°C). The supernatant was re-centrifuged at 20000 x g for15 
min at 4°C. The QIAGEN-tip 100 was equilibrated by applying 4ml of QBT 
Buffer and allowing the column to empty by gravity flow. The supernatant was 
added to the QIAGEN-tip, which was then washed with 2 times 10ml of QC 
Buffer. The DNA was eluted with 5ml of QF Buffer into a clean 15ml vessel. By 
adding 3.5ml of isopropanolol to the eluted DNA, the DNA was precipitated. 
After a centrifugation at 15000 x g for 30min at 4°C the supernatant was 
carefully decanted. The DNA pellet was washed with 2ml of 70% ethanol and 
centrifuged at 15000 x g for 10min. The supernatant was discarded. The pellet 
was air-dryed for 5-10min and the DNA was redissolved in TE buffer (pH 8.0).  
 
3.5.2 Reverse transfection protocol 
siRNA (20pmol) or plasmid (0.2µg) were diluted in 5µl serum free DMEM high-
glucose medium and gently pipetted up and down. Three times as much Polyjet 
was diluted in 5µl serum free DMEM high-glucose medium and carefully 
pipetted up and down. The PolyJet was added all at once to the siRNA/plasmid 
dilution and pipetted up and down 3-4 times. It is critical to not mix the solutions 
in reverse order. The mixture was incubated for 10-15min at room temperature. 
10µl of the PolyJet-siRNA/clone-mixture was added to each well of a 96-well 
culture plate. 2 x 104 cells/well in 20% FBS were added to each well. After 5h 
the medium was replaced with the day 0 differentiation media, as described 
above.  
 
3.6 RNA isolation and quantitative real time PCR analysis 
For RNA isolation OP9 cells and primary preadipocytes were cultured and then 
collected in 1ml TRIzol reagent (if cultured in a 6-well plate) or using the Direct-
zol RNA isolation kit from Zymo Research, Irvine, CA, USA (if cultured in a 96-
well plate).  
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3.6.1 TRIzol – RNA isolation 
The media of confluent OP9 cell or primary preadipocytes 6-well culture plates 
was sucked off using a 1000µl-pipette. The cells were washed 2 times with 
PBS, which was removed afterwards. To each well 1ml of TRIzol reagent was 
added, the cells were scraped from the well, the lysate was pipetted up and 
down several times to homogenize and was then placed into a 1.5ml cornical 
plastic flask. The lysate was centrifuged for 5min at 12000 x g at 4°C and the 
clear supernatant was transferred to a new tube, followed by a 5-min-incubation 
at room temperature to permit complete dissociation of the nucleoprotein 
complex. Per 1ml of TRIzol reagent used for lysis, 0.2 ml of chloroform was 
added, and the mix was incubated for 2-3min at room temperature. Then the 
sample was centrifuged for 15min at 12000 x g at 4°C. The mixture seperated 
at this step into a lower red phenol-chloroform, an interphase, and a colorless 
upper aqueous phase. The aqueous phase, containing the RNA, was 
transferred to a new tube by angling the tube at 45°C and pipetting the solution 
out. Per 1ml of TRIzol reagent used for lysis, 0.5ml of isopropranolol was added 
to the aqueous phase and was incubated for 10min at room temperature. After 
centrifuging the mixture for 10min at 12000 x g at 4°C the RNA precipitate 
formed a white gel-like pellet at the bottom of the tube. The supernatant was 
discarded with a micropipettor. The pellet was resuspended in 1ml of 75% 
ethanol per 1ml of TRIzol Reagent used for lysis. The sample was briefly 
vortexed and then centrifuged for 5min at 7500 x g at 4°C. The last step was 
repeated one more time. After centrifugation the supernatant was discarded 
with a micropipettor and the RNA pellet was air dryed for 5-10min. After drying, 
the RNA pellet was resuspended in 30µl RNAse free water.  
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3.6.2 Direct-Zol – RNA isolation 
The cells were lysed in 100µl of TRI Reagent and mixed thoroughly. An equal 
volume of ethanol (95-100%) was added to the sample lysed in TRI Reagent 
and mixed completely. The mixture was transferred into a Zymo-Spin IIC 
Column in a collection tube and centrifuged at 12000 x g for 30s. The column 
was moved to a new collection tube and the flow-through was discarded. RNA 
Wash Buffer (400µl) was added to the column and centrifuged at 12000 x g for 
30s. In an RNase-free tube a mixture of 5µl DNase I and 75µl DNA Digestion 
Buffer was prepared, which was then added directly to the column matrix. The 
column was incubated at room temperature for 15min. Direct-zol RNA PreWash 
(400µl) was added to the column and centrifuged at 12000 x g for 30s. The 
flow-through was discarded and the previous step was repeated one more time. 
RNA Wash Buffer (700µl) was added to the column and centrifuged at 12000 x 
g for 2 min to ensure complete removal of the Wash Buffer. The column was 
carefully transferred to a RNase-free tube. To elute the RNA, 50µl of 
DNase/RNase-free water was directely added to the column matrix and 
centrifuged at 12000 x g for 30s. 
 
3.6.3 Measurement of RNA concentration 
For measuring the RNA concentration, the NanoDrop 1000 Spectrophotometer 
by Thermo Scientific was used. A volume of 1µl of the sample was pipetted 
onto the end of a sampling arm. This sampling arm contains a fibre optic cable. 
The sampling arm was closed and therefore the second fibre optic cable came 
into contact with the sample causing the liquid to bridge between both fibre 
optic ends. By using a pulsed xenon flash lapm a s a light source a spectral 
measurement was made. The NanoDrop 1000 Spectrophotometer is linked to a 
computer with a special software, which saves the measured RNA 
concentration directly in a file.  
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3.6.4 First-Strand cDNA synthesis using SuperScript II Reverse 
Transcriptase 
 
A 20-µl reaction volume was used for 1ng to 5µg of total RNA  
1) The following components were added to a nuclease-free microcentrifuge 
tube 
50 to 250ng random primers 1µl 
1ng to 5µg total RNA  x µl (calculated based on the 
NanoDrop RNA concentration of 
sample) 
1µl dNTP mix (10 mM each) 1µl 
Sterile, distilled water  up to 12µl 
2) The mixture was heated to 65°C for 5min and quickly chilled on ice before 
the contents of the tube were collected by brief centrifugation and the following 
components were added 
5X First-Strand Buffer  4µl 
0.1M DTT  2µl 
RNaseOUT (40 units/µl) 1µl 
3) The contents of the tube were mixed gently and the tube was incubated at 
25°C for 2min 
4) 1µl (200 units) of SuperScript II RT was added and mixed by pipetting gently 
up and down and then incubated at 25°C for 10min 
5) The mixture was incubated at 42°C for 50min 
6) The reaction was inactivated by heating the mix at 70°C for 15min 
 
 
3.6.5 Real-time PCR 
After converting RNA into cDNA a real-time PCR was performed using an ABI 
Prism 8500 System using SYBR green maxter mix reagent. The relative mass 
of specific RNA was calculated by the comparative cycle of threshold detection 
method according to the manufacturer’s instruction. Genes examined included: 
Plin1, Hsl, Fabp4, Slc22a15, Slc43a3, Slc16a6, Slc45a3, Slc25a33, Slc35c2, 
Abcd4. 
Supplemental Table S2 shows the primer sets used for each gene.  
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3.7 Fatty acid uptake assay 
OP9 cells were seeded into a black-wall/clear-bottom 96-well plate (Costar), 
transfected with Slc43a3 Pre-designed Silencer Select siRNA or scrambled 
siRNA following a reverse transfection protocol and then cultured for 120h (5 
days) according to the differentiation protocol (described above). On day 5, a 
FA uptake assay was performed according to the manufacturers protocol. 
Briefly, the medium was removed from the wells and replaced with 90µl/well 
serum free medium and 10µl/well HBSS (1x) containing 0.2% fatty acid free 
bovine serumalbumin (BSA). The assay plate was then incubated for 1h at 
37°C, 5% CO2. Before the test compound was added, a time zero read was 
performed. 100µl of the test compound, diluted in HBSS (1x) and 0.2% BSA 
was added to each well and immediately read in a fluorescence microplate 
reader for a kinetic reading at 485mm (every 30s for 30min) using a bottom-
read mode. 
 
3.8 Quencher-based free fatty acid efflux assay 
The efflux assay was conducted as previously described (24) with minor 
modifications. OP9 cells (2 x 104) were seeded into a black-wall/clear-bottom 
96-well plate (Costar), transfected with Slc43a3 Pre-designed Silencer Select 
siRNA or scrambled siRNA following a reverse transfection protocol and then 
cultured for 120h (5 days) according to the differentiation protocol for OP9 cells. 
The cells were then loaded with 2µM of the fluorescent lipid BODIPY C1-C12 
bound to 1%BSA in HBSS (1x) for 16h. After washing the assay plates with 
PBS, 100µl of fresh buffer containing HBSS (1x) with 1%BSA buffer and 
BackDrop GREEN Background Supressor Ready Probe Reagent 2 drops/ml 
(Molecular Probes by Life Technologies) were added and the wells were once 
read for an initial time zero reading at 24°C. Half of the wells of each group 
were then stimulated with 20µM forskolin and 1mM isobutyl-methylxanthine. 
The assay plates were read for 30min in a fluorescent plate reader utilizing a 
bottom-read setting (kinetic, 485mm). 
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3.9 Cyclic adenosine monophosphate assay 
A cyclic adenosine monophosphate (cAMP) complete enzyme immunoassay kit 
(Enzo Life Sciences, Farmingdale, NY, USA) was used to measure forskolin-
induced cAMP formation intra- and extracellularly. Differentiated OP9 cells were 
incubated for 60min with or without lipolytic stimuli (20µM forskolin, 1mM 
isobutyl-methylxanthine) bound to 1%BSA in HBSS (1x) at 37°C and 5% CO2. 
The incubation media was collected, and the cells were extracted using 0.1M 
HCl to avoid degradation of cAMP, and cAMP levels were measured in whole 
cell lysates as well as the media by using the complete cAMP immunoassay kit 
(Enzo Life Sciences) according to the manufacturer’s instructions. The level of 
cAMP production was normalized to the amount of total protein. 
 
3.10 Western blot 
Cells were lysed with 100-150µl of Ripa Buffer (with proteinkinase inhibitor) per 
1 well of 6 well culture plate and sonicated with 10 bursts per tube (on ice). The 
tubes were spun for 10min at 1000 x g at 4°C. The supernatant was pipetted to 
a new Eppendorf tube and the protein concentration was determined using a 
protein concentration assay kit. 
BSA was used for the standard curve (blank, 0.2µg, 0.4µg, 0.6µg, 1µg, 1.5µg, 
2µg, 3µg – added up with 150µl of autoclaved, distilled water). 1 well was only 
pipetted with Ripa Buffer. 1µl of sample was added up to 150µl of autoclaved, 
distilled water and incubated for 2h and then read at 652nm. After plotting the 
standard curve, the protein concentration of each sample was calculated. 
15-20µg of protein was used for the western blot. 1.5-2 times as much 4X 
loading buffer was added to each sample and heated at 100°C for 10min. The 
tubes were quickly spun at 12000 x g for 30s. The gel was placed in the voltage 
equipment and loaded with the proteins and the marker. It was run at 125-200 
Volt (V) for ca. 1h. The gel was then washed in 1X transfer buffer with 20% 
methanol. Membrane, polster and gel were prepared in a clip-bag and placed in 
the voltage machine and ran for 45min – 1h in 4°C with 80V. The membrane 
was peeled from the clip-bag, placed in a little black box and blocked with 
blocking gel (no antibody was added at this point) for 30min on a plate shaker. 
Afterwards the old blocking gel was discarded and a new one was added as 
well as the antibody, mostly in a 1:1000 dilution (housekeeping antibody: beta-
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actin). The box with the membrane was placed on a plate shaker at 4°C 
overnight. The next day the membrane was washed 3 times for 10min with 
phosphate-buffered saline with Tween 20 (PBST) and then incubated for 1h at 
room temperature with the secondary antibody (diluted 1:15000). The 
membrane was washed again 2 times for 10min with (PBST) and then one time 
with PBS before being scanned.  
 
3.11 Statistics 
Data are expressed as means ± SEM. Statistical analyses were performed by 
one-way ANOVA using Prism 6.02 for Mac OS X (GraphPad Software, Inc., La 
Jolla, CA, USA). To evaluate the differences in Table 1, a t-test was performed. 
Differences between groups were considered statistically significant when 
P<0.05. 
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4 Results 
 
4.1 mRNA expression levels of membrane transport proteins in patients 
before and after bariatric surgery 
Patients who undergo bariatric sugery show major changes in fat metabolism. 
Since caloric intake is significantly reduced, FA efflux is expected to be 
substantially increased. In search of genes that are potentially involved in FA 
transport, particularly any potentially involved in FA efflux, the mRNA 
expression levels of 22 membrane transport proteins from the ABC transporter 
family and 33 from the SLC family (see list in Supplemental Table S1) were 
examined in the adipose tissue of patients post bariatric surgery at this critical 
time. At the time of the study these membrane transport proteins did not have a 
known ligand. Table 1 shows the expression levels, determined using branched 
DNA analysis, of genes that displayed statistically significant differences before 
(pre-op) and one-week after bariatric surgery (post-op). Of the genes examined, 
eight genes from the SLC family showed significant increases after bariatric 
surgery and six showed significant decreases. The functions of these SLC 
family members have not yet been determined. 
 
 
 
Pre-op 
ave. (/TBP) 
Post-op 
ave. (/TBP) 
Fold 
Post/Pre 
T test 
ABC transporter family 
ABCC10 0.157 0.246 1.567 0.002 
ABCD4 0.789 1.181 1.497 0.009 
ABCB10 0.646 0.942 1.459 0.016 
ABCA6 4.636 2.273 0.490 0.017 
ABCA5 0.460 0.196 0.426 4.78E-04 
ABCA10 1.680 0.586 0.349 1.51E-04 
ABCA9 3.122 1.073 0.344 0.002 
ABCA8 3.878 1.229 0.317 0.002 
ABCC6 1.242 0.208 0.167 9.49E-05 
ABCD2 3.385 0.564 0.167 7.99E-06 
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Pre-op 
ave. (/TBP) 
Post-op 
ave. (/TBP) 
Fold 
Post/Pre 
T test 
SLC transporter family 
SLC22A15 0.005 0.062 11.808 6.96E-06 
SLC16A6 0.060 0.379 6.271 0.014 
SLC45A3 0.066 0.244 3.680 0.006 
SLC35F2 0.065 0.226 3.460 0.044 
SLC43A3 1.151 2.791 2.424 0.012 
SLC16A5 0.136 0.280 2.058 0.001 
SLC35C2 0.922 1.734 1.880 0.001 
SLC35E3 0.372 0.531 1.428 0.054 
SLC25A46 1.740 1.197 0.688 4.48E-05 
SLC25A30 0.863 0.562 0.652 1.22E-04 
SLC25A36 0.975 0.531 0.545 0.001 
SLC25A42 0.441 0.191 0.432 0.001 
SLC25A33 1.780 0.627 0.352 2.19E-04 
SLC6A16 0.073 0.011 0.153 0.001 
P450 superfamily  
TBXAS1 0.942 2.882 3.059 0.001 
Leukotriene metabolism  
LTA4H 2.191 3.617 1.651 0.028 
LTB4R 0.258 0.422 1.636 0.026 
CYSLTR1 0.873 0.614 0.703 0.040 
Others  
SIRT3 0.770 0.619 0.804 0.012 
GSTA4 0.895 0.493 0.550 0.001 
PDE3B 3.764 0.810 0.215 0.005 
 
Table 1 mRNA expression levels of membrane transport proteins in patients 
before and after bariatric surgery showing statistically significant changes. 
Genes that will be further examined are printed in bold.  
 
Genes that showed the most significant changes were Slc22a15, Slc43a3, 
Slc16a6, Slc45a3, Slc25a33 and Slc35c2 and Abcd4. In further experiments it 
will be studied how these genes expess in varios tissues involved in the energy 
metabolism (liver and adipose tissues) and how their expression levels change 
throughout differentiation.   
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4.2 mRNA expression of membrane transporters in mouse tissues, OP9 
cells and primary preadipocytes 
 
4.2.1 mRNA expression of membrane transporters in mouse tissues 
Liver and fat tissue are the main participants in energy metabolism. Hence, it 
was assumed that genes, which are involved in FA transport, must express 
highly in liver and adipose tissue. Therefore, mRNA expression levels of the six 
plasma membrane proteins of the SLC family that showed substantial basal 
expression levels and more than a 1.5-fold increase (see Table 1) after bariatric 
surgery were further analyzed in murine liver and various fat tissues 
(epicutaneous, subcutaneous and brown adipose tissue). For this analysis, four 
months old male wild type C57Bl6 mice were sacrificed and their liver and fat 
tissues were collected for analyis of mRNA expression by RT-qPCR. From all 
analyzed genes Slc43a3 showed the most significant expression in 
epicutaneous, subcutaneous and brown adipose tissue (Figure 3). Its 
expression pattern is comparable to genes that are involved in control of lipid 
homeostasis in adipose tissue, ie. Plin1, Hsl and Fabp4. 
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Figure 3. Levels of membrane transporter mRNA in wildtype mouse liver, 
epicutaneous fat, subcutaneous fat and brown adipose tissue, each with n=4. 
Plin1, HSL and Fabp4 are known genes involved in fat metabolism. Slc22a15, 
Slc43a3, Slc16a6, Slc45a3, Slc45a3, Slc22a33, Slc35c2 and Abcd4 are genes 
that showed a significant change in mRNA expression levels before and after 
bariatric surgery. The function of these genes has not been determined yet.   
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4.2.2 mRNA expression of membrane transporters in OP9 cells and 
primary preadipocytes 
During differentiation from preadipocytes to adipocytes mRNA expression levels 
of genes that are involved in energy metabolism are expected to increase. This 
effect can be seen in Figure 4A and 4B: apart from Plin1, the lipid-droplet 
associated protein, also Fabp4, the common indicator for lipid 
accumulation/adipocyte maturity, increases significantly throughout 
differentiation. Though not only the familiar genes (Plin1, Hsl and Fabp4) but 
also the so far unknown genes like Slc22a15, Slc43a3, Slc16a6, Slc25a33, 
Slc35c2 and Abcd4 showed significant changes. Out of all the genes that are 
named above, Slc43a3 showed the most significant changes in mRNA 
expression levels. The differentiation of OP9 cells from preadipocytes to 
adipocytes showed that expression of Slc43a3 increased significantly between 
day 0 and day 9 (P<0.01) and between day 3 and day 9 (P<0.05) (Figure 4A). 
The gene expression was also studied in primary preadipocytes, which were 
isolated from wildtype mice, and differentiated for 14 days. As shown in Figure 
4B, again Slc43a3 displayed the most significant changes in expresssion 
throughout differentiation: between day 0 and day 3 (P<0.05), between day 3 
and day 9 (P<0.001) and between day 0 and day 9 (P<0.001). These results 
imply that Slc43a3 plays a significant role in lipid metabolism.  
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Figure 4. mRNA expression of membrane transporters in OP9 cells and 
primary preadipocytes.  
(A) Levels of membrane transporter mRNA in OP9 cells. OP9 cells were treated 
with 0.5mM isobutyl-methylxanthine, 1µM dexamethasone and 1µg/ml insulin 
for differentiation for 5 days before mRNA analysis. Results are representative 
of 3 independent experiments, each with n=6. (B) Levels of membrane 
transporter mRNA in differentiated primary mouse preadipocytes. Results are 
representative of 3 independent experiments, each with n=6. * p<0.05, ** 
p<0.01, *** p<0.001. 
 
4.3 Knockdown and overexpression of Slc43a3 
To characterize the function of Slc43a3, the levels of Slc43a3 in OP9 cells were 
manipulated by knockdown using siRNA or overexpression (pEZ-M51-Slc43a3) 
and the cells were examined after 5 days of differentiation.  
 
4.3.1 Confirmation of the expression levels of Slc43a3  
To further study the effect of Slc43a3 on fat metabolism, Slc43a3 was 
inhibited/overexpressed in OP9 cells. The expression levels of Slc43a3 in 
transfected and control (scrambled siRNA; pcDNA6) cells were detected by RT-
qPCR (Figure 5A) and western blot (Figure 5B). When Slc43a3 siRNA was 
transfected into the cells, Slc43a3 mRNA expression significantly decreased 
(P<0.05), whereas transfection of cells with pEZ-M51-Slc43a3 significantly 
increased Slc43a3 expression compared to control (P<0.001) (Figure 5A). In 
this experiment it was also investigated if knockdown/overexpression of 
Slc43a3 has a significant effect on the mRNA expression levels of popular 
genes involved in lipid transport, including SR-B1, CD36, HSL, ATGL, CGI58, 
G0S2, FATP1 and Plin1, but no link could be found. This data suggests that 
Slc43a3 is independantly affecting fat metabolism.  
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5 A 
 
 
 
5 B 
 
 
 
Figure 5. Confirmation of the expression levels of Slc43a3. 
(A) Levels of Slc43a3 mRNA and other genes involved in adipose metabolism 
in OP9 cells after transfection with scrambled siRNA (control), Slc43a3 siRNA, 
pcDNA6 (control) or pEZ-M51-Slc43a3-His clone. Results are representative of 
3 independent experiments, each with n=4. (B) Western blot of Slc43a3 in OP9 
cells transfected with scrambled siRNA (control), Slc43a3 siRNA, pcDNA6 
(control) or pEZ-M51-Slc43a3-His clone. 
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4.3.2 Difference in lipid droplet accumulation 
During the differentiation process, the synthesis of TAG increases and the 
differentiated cells obtain the behaviour of adipose cells. TAG, especially, 
gather in lipid droplets embedded in the cytoplasm. Lipid droplets are cellular 
organelles that manage the storage and hydrolysis of neutral lipids, including 
TAG and cholesterol esters (40). Figure 6 shows the difference in lipid droplet 
accumulation using fluorescent microscopy. There was significantly more 
accumulation of lipid droplets in OP9 cells at day 5 after differentiation with 
knockdown of Slc43a3, whereas overexpression of Slc43a3 resulted in a 
significant decrease in lipid accumulation (Figure 6).  
 
 
 
Figure 6. Lipid accumulation in differentiated OP9 cells transfected with 
scrambled siRNA (control), Slc43a3 siRNA, pcDNA6 (control) or pEZ-M51-
Slc43a3-His clone. OP9 cells were transfected with the scrambled siRNA 
(control), Slc43a3 siRNA, pcDNA6 (control) or pEZ-M51-Slc43a3-His clone and 
differentiated for 5 days. 1 nM Bodipy 493/503 were added to the media before 
fluorescent microscopy. Results are representative of 3 independent 
experiments. 
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4.3.3 Effects of Slc43a3 knockdown and overexpression on free fatty acid 
uptake 
The aim of this study was to find genes that are involved in FA transport. Figure 
7 shows the result of direct measurements of FA uptake with knockdown and 
overexpression of Slc43a3. When cells were transfected with Slc43a3-siRNA a 
significantly increased rate of FA uptake (P<0.001) was observed, whereas 
overexpression of Slc43a3 significantly decreased the rate of FA uptake 
(P<0.001). As a result, it can be concluded that Slc43a3 is a negative regulator 
of FA uptake.  
 
 
 
 
Figure 7. Effects of knockdown and overexpression of Slc43a3 in OP9 cells on 
free FA uptake. Results are representative of 2-3 independent experiments. 
Slc43a3 knockdown: n=22; Slc43a3 overexpression: n=12; Control combined: 
n=36. * p<0.05, ** p<0.01, *** p<0.001. RFU = relative fluorescence units. 
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4.3.4 Effects of Slc43a3 knockdown and overexpression on free fatty acid 
efflux 
The impact of Slc43a3 on FA efflux was also examined. Interestingly, 
knockdown of Slc43a3 significantly (P<0.05) decreased the rates of FA efflux 
compared to control cells under basal conditions and substantially (P<0.01) 
blunted FA efflux when cells were treated with forskolin to stimulate lipolysis 
and FA efflux (Figure 8). This data suggests that Slc43a3 is a positive regulator 
of FA efflux. Although a final conclusion can’t be drawn yet, since until today it 
wasn’t possible to study the effect of Slc43a3 overexpression on FA efflux. 
These experiments should be conducted in the future to better comprehend the 
possible influence of Slc43a3 overexpression on FA efflux.  
 
 
 
 
 
Figure 8. Effects of knockdown of Slc43a3 in OP9 cells on FA efflux. Results 
are representative of 3-4 independent experiments with replication of 9 in each 
treatment. * p<0.05, ** p<0.01. AUC = area under the curve.  
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4.4 Expression of Slc43a3 in CD36 knockout mice 
CD36 is known to be important in FA transport and regulation, such that there is 
decreased FA uptake in adipose tissue of CD36 KO mice. Therefore, the 
expression levels of Slc43a3 were examined in adipose tissues of CD36 KO 
mice. As shown in Figure 9A, there is a significant upregulation of expression of 
Slc43a3 (P<0.05) compared to control (wildtype mice) in both, the 
subcutaneous and retroperitoneal adipose tissue of CD36 KO mice. To further 
explore this possible relationship, the expression of both, Slc43a3 and CD36, 
were manipulated in OP9 cells. OP9 cells were transfected with Slc43a3 siRNA, 
CD36 siRNA, both Slc43a3 and CD36 siRNA at the same time or with control 
scrambled siRNA. Data presented in Figure 9B shows that knockdown of CD36 
decreases the rate of FA uptake as compared to control, consistent with prior 
observations (41). Compatible with prior data shown in Figure 7, knockdown of 
Slc43a3 again increased the rate of FA uptake compared to control. Figure 9C 
shows the accumulative effect on FA uptake of CD36, Slc43a3 and 
CD36+Slc43a3 knockdown compared to control. Interestingly, when both CD36 
and Slc43a3 were knocked down, the rate of FA uptake was similar to control, 
suggesting that the effects of Slc43a3 are mediated independently from CD36. 
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Figure 9. Exploration of the relation between Slc43a3 and CD36. 
(A) Levels of Slc43a3 RNA in adipose tissue of wildtype and CD36 KO mice. 
Total RNA was prepared from subcutaneous and retroperitoneal adipose 
tissues from wild type and CD36 knockout mice. Levels of Slc43a3 were 
assayed using Taqman RT-PCR as described in the methods. Results are a 
summary of three independent assays with n=3-4 in each group. (B) Effects of 
Slc43a3, CD36 and double knockdown in OP9 cells on free FA uptake 
compared to control (scrambled siRNA). (C) AUC of FA uptake for the first 6 
minutes. Results are representative of 3 independent experiments, each with 
n=8. * p<0.05, ** p<0.01, *** p<0.001.  
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4.5 Effects of Slc43a3 on cAMP levels 
In exploring potential mechanisms through which Slc43a3 might influence 
cellular homeostasis, the changes in cAMP levels with either knockdown or with 
overexpression of Slc43a3 were examined, since cAMP is known to be a 
component in lipogenesis and lipolysis. Interestingly, the knockdown of Slc43a3 
caused a reduction in cAMP extracellularly (P<0.001), as well as intracellularly 
(P<0.05) following treatment with forskolin and isobutyl-methylxanthine. 
Surprisingly, overexpression of Slc43a3 also caused a small reduction in 
extracellular cAMP following treatment with forskolin and isobutyl-
methylxanthine (17.45±0.04 pmol/ml control versus 15.14±0.62 pmol/ml 
overexpression, P<0.05). 
 
 
 
 
Figure 10. Effects of Slc43a3 on cAMP levels. AMP was measured by ELISA. 
Changes of extra- and intracellular cAMP levels after transfection with Slc43a3 
siRNA and pEZ-M51-Slc43a3-His clone in OP9 cells and treatment with 
forskolin and isobutyl-methylxanthine. Results are representative of 2 
independent experiments, each with n=4.  
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5 Discussion 
 
5.1 Slc43a3 was identified as a major player in lipid metabolism 
As a cell with endocrine function, adipocytes actively take up and release FAs 
under different physiological conditions, contribute to the regulation of lipid 
homeostasis, and, in turn, participate in whole body metabolism. Dysregulation 
of FA metabolism is a major factor contributing to the development of disorders 
such as diabetes, cardiovascular disease and non-alcoholic fatty liver disease. 
In that regard it seemed necessary to further explore possible components of 
the regulation of lipid homeostasis, considering that their modification could 
have a major impact on the treatment of obesity-related disorders.  
Bariatric surgery has been shown to be the most effective treatment of obesity 
and obesity related type 2 diabetes (45–47). One of the interesting observations 
is that one-week post-surgery, most patients have improved insulin sensitivity 
without substantial weight loss (48). Studies have displayed that in response to 
the major changes of bariatric surgery, several main regulators of adipose 
tissue metabolism, such as PPARγ, PPARδ and UCP2, have altered expression 
during the first week post-surgery, attenuating lipid storage and promoting fatty 
oxidation (38). Indeed, FA efflux would be expected to be markedly increased at 
this time since caloric intake is substantially reduced. This is why this timepoint 
of dramatic metabolic changes post-bariatric surgery was choosen to search for 
potential regulators of FA transport in adipocytes. It was observed that there are 
many alterations in adipocyte plasma membrane transporters, which currently 
have unknown functions, during this first week of metabolic transition. 
The biggest change in mRNA expression levels before and after bariatric 
surgery could be observed in genes from the transporter families of the ATP-
binding cassette (ABC) transporters and the Solute Carriers (SLC). We could 
show that from the 22 membrane transport proteins of the ABC transporter 
family and 33 of the SLC family, 10 and respectively 14 changed significantly, 
which suggests that they are involved in lipid metabolism. For the advanced 
search of possible transport proteins, the fold post-op vs. pre-op was calculated 
and if it was greater than 1.5, the mRNA expression levels of these genes were 
further analyzed throughout differentiation in murine OP9 cells and primary 
preadipocytes. On the basis of its significant changes in mRNA expression, the 
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gene Slc43a3 came into focus and became the core of this study. The 
hypothesis, that a gene which is highly expressed in adipose tissue and 
increases its expression throughout differentiation has to be somehow involved 
in fat metabolism, holds true. The results of the FA uptake as well as the FA 
efflux assays demonstrated that Slc43a3 significantly influences FA transport. 
When cells were transfected with Slc43a3-siRNA the uptake rates of FA 
increased significantly, whereas when Slc43a3 was overexpressed the uptake 
rates decreased significantly. Furthermore, a knockdown of Slc43a3 resulted in 
significantly decreased FA efflux rates. To better understand the mode of action 
of Slc43a3, different approaches were chosen. For now, no final conclusion can 
be drawn but it seems that Slc43a3 is acting seperatly from popular genes 
involved in fat metabolism, especially CD36. In addition, it was observed that 
Slc43a3 affects cAMP production, but it appears that FA flux is independent of 
this effect. 
 
5.2 Slc43a3 shows significant expression in adipose tissue and 
throughout adipocyte differentiation 
The SLC family is one of the two transporter super families and consists of 
more than 400 members. SLC transporters are predominantly facilitative or 
secondary-active. For the movement of substrates across membranes SLCs 
need an electrochemical gradient. In order for SLCs to transport substrates 
against a concentration gradient, they need ion gradients that are generated by 
ATP-dependent pumps (34). 
In this study eight genes from the SLC family were identified to increase 
significantly (SLC22A15, SLC16A6, SLC45A3, SLC35F2, SLC43A3, SLC16A5, 
SLC35C2, SLC35E3) after bariatric surgery and six to significantly decrease 
(SLC25A46, SLC25A30, SLC25A36, SLC25A42, SLC25A33, SLC6A16). The 
functions of these SLC family members have not yet been determined.  
One of the SLC transporter genes that demonstrated increased expression after 
bariatric surgery (2.5 fold) was Slc43a3. The SLC43 family of transporters is 
composed of only three members: two amino acid system L transporters (LAT3 
and LAT4) and the orphan transporter EEG1 (embryonic epithelia gene 1) (49–
51). Human LAT3 and LAT4 share ca. 57% amino acid sequence identity, 
whereas human EEG1 is a distant member of the family with only ca. 27% 
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amino acid sequence identity with the other two members. Mouse Eeg1 was 
identified as a gene expressed in a cellular model of renal tubulogenesis (51) 
and the human gene has been assigned as SLC43A3 (52). However, its 
specific function in adipose tissue and its involvement in lipid metabolism had 
not yet been investigated prior to the current studies. Slc43a3 was shown to be 
expressed during embryogenesis in liver and lung and has recently been 
reported to be involved in the cellular uptake of extracellular purine nucleobases 
(53). 
The analysis of mRNA expression in normal adult control mice revealed that the 
expression of Slc43a3 in adipose tissues is similar to that in the liver. Slc43a3 
showed in epicutaneous, subcutaneous and brown adipose tissue, compared to 
all other examined genes, the most significant mRNA expression levels. These 
expression levels can be compared with genes that are involved in control of 
lipid homeostasis in adipose tissue, such as Plin1, Hsl and Fabp4. The in vitro 
study in a murine OP9 adipocyte cell line and in primary mouse preadipocytes 
indicated that Slc43a3 expression is induced during the differentiation of 
adipocytes. The differentiation of the OP9 cells and primary mouse 
preadipocytes with 0.5mM isobutyl-methylxanthine and 1µM dexamethasone 
on day 0 and with 1 µg/ml insulin on day 2, resulted in increasing levels of 
Slc43a3 expression. Other, yet unidentified transporter genes, showed not as 
significant changes at this point.  
The continuous and significant increase of Slc43a3 throughout differentiation 
suggests that Slc43a3 is playing a major role in lipid metabolism.  
 
5.3 Slc43a3 is a regulator of free fatty acid flux 
The experiments of this project were designed in order to understand the 
molecular mechanisms and regulations of FA flux better. Therefore, it was 
necessary to construct assays that allowed the observation of FA transport, 
such as FA uptake and FA efflux assays (25). Among the construction of FA 
transport assays, Slc43a3 needed to be overexpressed/knocked down with an 
appropriate clone/siRNA.  
Interestingly overexpression of Slc43a3 in OP9 cells resulted in significantly 
lower (P<0.001) rates of FA uptake and lipid accumulation in the cells, whereas 
siRNA mediated knockdown of Slc43a3 resulted in significantly higher 
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(P<0.001) rates of FA uptake and increased lipid accumulation in cells. 
Surprisingly, knockdown of Slc43a3 significantly decreased the rates of FA 
efflux compared to control cells under basal conditions (P<0.05) and 
substantially blunted FA efflux when cells were treated with forskolin to 
stimulate lipolysis and FA efflux (P<0.01). Thus, Slc43a3 appears to influence 
fatty acid flux in adipocytes, functioning as a positive regulator of fatty acid 
efflux and as a negative regulator of fatty acid uptake. 
 
5.4 Possible mechanisms of Slc43a3 
This study could state that Slc43a3 has a significant impact on free fatty acid 
efflux. To explore potential mechanisms whereby Slc43a3 might be altering 
rates of FA flux a cAMP assay was performed. cAMP and cAMP-dependant 
protein kinase A (PKA) signaling pathways are known to be involved in 
lipogenesis and the lipolysis process (54). The performed cAMP assay 
displayed that both knockdown, as well as overexpression of Slc43a3, reduced 
forskolin-stimulated cAMP generation. Although an explanation for how both 
knockdown and overexpression of SLC43a3 reduce forskolin-stimulated cAMP 
remains obscure, the observations suggest that any Slc43a3 mediated changes 
in FA flux are independent of its effects on cAMP production. 
In the search for other possible ways how Slc43a3 could be acting, the effect of 
Slc43a3 knockdown and overexpression was studied compared to expression 
levels of genes that are known to be involved in cellular FA and lipid 
metabolism. But neither the knockdown nor the overexpression of Slc43a3 had 
any significant effect on the mRNA expression of genes, such as SR-B1, CD36, 
HSL, ATGL, CGI58, G0S2, FATP1 and Plin1.  
To make sure that the observed effects were not caused by an unknown 
relationship between Slc43a3 and CD36, the rate of FA uptake was measured 
in si-Slc43a3, si-CD36 and si-CD36+Slc43a3 transfected OP9 cells. 
Knockdown of Slc43a3, according to prior experiments from this study, 
increased the FA uptake. As expected, knockdown of CD36, decreased FA 
uptake, since CD36 is known as the predominant transporter of FAs into 
adipocytes. However, when both genes were knocked out (si-CD36+Slc43a3) 
the rate of the FA uptake was similar to control. This suggests that actions of 
Slc43a3 on FA uptake are independent of CD36 expression. The mechanism(s) 
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through which Slc43a3 mediates these effects on FA flux remains to be 
elucidated and is the focus of ongoing studies. 
Nonetheless, it would appear that Slc43a3 is not directly involved in FA flux, but 
somehow either influences the function of other proteins involved in facilitating 
FA flux or affects the diffusion or flip-flop of FAs across the PM. In regard to the 
latter possibility, we speculate that Slc43a3 might be involved in maintaining the 
electroneutrality of the cell during FA flux, functioning either as a symporter or 
antiporter of protons, which would be required to offset the intracellular changes 
associated with the flux of FA anions.  
 
5.5 Limitations of this study 
As with many studies, the experiments performed in this study have limitations. 
In this study, it was assumed that after bariatric surgery FA storage is 
attenuated and therefore FA mobilization from adipose tissue is favoured as 
caloric intake is reduced. In regard to the identification of proteins involved in FA 
transport, it would be interesting to assess whether the expression of Slc43a3 is 
differentially modulated in post prandial and fasting stage and whether this 
modulation is impacted by an obesogenic diet. Moreover, changes in Slc43a3 
are described during adipocyte differentiation but no experiments were 
performed demonstrating if knockdown or overexpression might influence 
adipocyte differentiation itself. It would be helpful to examine the effect of each 
treatment on various adipocyte differentiation markers. Furthermore, the FA 
uptake assay used in this study only investigated the uptake of medium chain 
fatty acids (BODIPY C1-C12). In additional studies it would be exciting to study 
if manipulating Slc43a3 expression has a similar impact on the uptake and 
efflux of long chain fatty acids (i.e. BODIPY FL-C16). Also, it was shown that 
cAMP levels changed when Slc43a3 was manipulated. The modulation of FA 
efflux might be related to changes in lipolysis activity, which would make the 
measurements of glycerol release in parallel to FA in the context of Slc43a3 
overexpression and knockdown attractive. 
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5.6 Summary 
This project was designed to find membrane-associated proteins that are not 
yet known to be involved in fatty acid transport. In an in-silico study genes 
encoding for proteins with unknown function, a plasma membrane location and 
a significant expression in adipose tissue, were searched for. These genes 
were studied in patients before and after bariatric surgery. In summary, more 
than 20 proteins (predominantly proteins from the ABC and SLC transporter 
families), without known function in lipid metabolism, could be identified to show 
significant change (P<0.05) after bariatric surgery. This alteration in expression 
levels indicates a possible involvement of these proteins in lipid homeostasis. 
The center of this study became the protein Slc43a3, coding for a membrane 
transporter of the SLC family. It was found that Slc43a3 is expressed highly in 
various adipose tissues, in the same extent as popular proteins involved in lipid 
metabolism, such as Plin1, Hsl and Fabp4. Furthermore, it was observed that 
Slc43a3 undergoes a significant upregulation throughout differentiation, which 
was studied in the murine OP9 cell line as well as in primary preadipocytes. 
However, the most exciting finding of this study is the substantial effect Slc43a3 
has on FA transport. Knockdown of Slc43a3 in OP9 cells lead to a significant 
increase (P<0.001) in FA uptake rates and lipid accumulation, while 
overexpression resulted in significantly decreased (P<0.001) rates of FA uptake 
and lipid accumulation. Slc43a3 also seems to have an effect on FA efflux since 
knockdown of Slc43a3 significantly lowered the rates of FA efflux compared to 
control cells under basal conditions (P<0.05) and substantially blunted FA efflux 
when cells were treated with forskolin to stimulate lipolysis and FA efflux 
(P<0.01). 
In the search for possible mechanisms for these actions, different approaches 
were pursued. First, it was investigated if knockdown/overexpression of Slc43a3 
has an effect on cAMP levels. Since, both reduce forskolin-stimulated cAMP 
levels significantly, it remains unclear how Slc43a3 is related to cAMP. 
However, the results suggest that any Slc43a3 mediated changes in FA flux are 
independent of its effects on cAMP production. 
Another hypothesis was that Slc43a3 does not influence FA transport itself, but 
rather influences one of the main proteins involved in lipid metabolism, such as 
SR-B1, CD36, HSL, ATGL, CGI58, G0S2, FATP1 and Plin1. Nevertheless, 
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neither knockdown nor overexpression presented any significant effect. 
Lastly, a potential relationship between Slc43a3 and CD36 was investigated. A 
FA uptake was performed in si-Slc43a3, si-CD36 and si-Slc43a3+CD36 
transfected OP9 cells. The outcome of these experiments suggests that the 
actions of Slc43a3 on FA uptake are independent of CD36 expression.  
Whatever its mechanism of action, it can be concluded that Slc43a3 regulates 
fatty acid flux in adipocytes, functioning as a positive regulator of FA efflux and 
as a negative regulator of FA uptake. Moreover, the demonstration that 
manipulating a plasma membrane protein can dramatically affect the ability of a 
cell to export FA provides a new direction for gaining a deeper understanding of 
the processes mediating FA flux in mammalian cells. 
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6 Supplemental data 
 
Supplemental Table S1. List of ABC transporters, SLC transporters and other 
genes screened. 
 Accession # Gene Symbol Species Locus ID 
1 NM_018672 ABCA5 HUMAN 23461 
2 NM_080284 ABCA6 HUMAN 23460 
3 NM_019112 ABCA7 HUMAN 10347 
4 NM_007168 ABCA8 HUMAN 10351 
5 NM_080283 ABCA9 HUMAN 10350 
6 NM_080282 ABCA10 HUMAN 10349 
7 NM_000194 HPRT1 HUMAN 3251 
8 NM_015657 ABCA12 HUMAN 26154 
9 NM_152701 ABCA13 HUMAN 154664 
10 NM_022717 SNRNP35 HUMAN 11066 
11 NM_007188 ABCB8 HUMAN 11194 
12 NM_019624 ABCB9 HUMAN 23457 
13 NM_012089 ABCB10 HUMAN 23456 
14 NM_001171 ABCC6 HUMAN 368 
15 NM_033450 ABCC10 HUMAN 89845 
16 NM_032583 ABCC11 HUMAN 85320 
17 NM_033226 ABCC12 HUMAN 94160 
18 NM_005164 ABCD2 HUMAN 225 
19 NM_002858 ABCD3 HUMAN 5825 
20 NM_005050 ABCD4 HUMAN 5826 
21 NM_001090 ABCF1 HUMAN 23 
22 NM_007189 ABCF2 HUMAN 10061 
23 NM_018358 ABCF3 HUMAN 55324 
24 NM_022169 ABCG4 HUMAN 64137 
25 NM_001442 FABP4 HUMAN 2167 
26 NM_001444 FABP5 HUMAN 2171 
27 NM_003355 UCP2 HUMAN 7351 
28 NM_000922 PDE3B HUMAN 5140 
29 NM_014037 SLC6A16 HUMAN 28968 
30 NM_032178 FLJ13291 HUMAN 84138 
31 NM_004695 SLC16A5 HUMAN 9121 
32 NM_004694 SLC16A6 HUMAN 9120 
33 NM_005495 SLC17A4 HUMAN 10050 
34 NM_030958 SLCO5A1 HUMAN 81796 
35 NM_080866 SLC22A9 HUMAN 114571 
36 NM_004803 SLC22A14 HUMAN 9389 
37 NM_018420 SLC22A15 HUMAN 55356 
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 Accession # Gene Symbol Species Locus ID 
38 NM_015482 SLC22A23 HUMAN 63027 
39 NM_001010875 SLC25A30 HUMAN 253512 
40 NM_032315 SLC25A33 HUMAN 84275 
41 NM_207348 SLC25A34 HUMAN 284723 
42 NM_201520 SLC25A35 HUMAN 399512 
43 NM_018155 SLC25A36 HUMAN 55186 
44 NM_178526 SLC25A42 HUMAN 284439 
45 NM_145305 SLC25A43 HUMAN 203427 
46 NM_014655 SLC25A44 HUMAN 9673 
47 NM_182556 SLC25A45 HUMAN 283130 
48 NM_138773 SLC25A46 HUMAN 91137 
49 NM_015945 SLC35C2 HUMAN 51006 
50 NM_001008783 SLC35D3 HUMAN 340146 
51 NM_024881 SLC35E1 HUMAN 79939 
52 NM_018656 SLC35E3 HUMAN 55508 
53 NM_001001479 SLC35E4 HUMAN 339665 
54 NM_001029858 SLC35F1 HUMAN 222553 
55 NM_017515 SLC35F2 HUMAN 54733 
56 NM_173508 SLC35F3 HUMAN 148641 
57 NM_001080455 SLC35F4 HUMAN 341880 
58 NM_025181 SLC35F5 HUMAN 80255 
59 NM_014096 SLC43A3 HUMAN 29015 
60 NM_033102 SLC45A3 HUMAN 85414 
61 NM_001080431 SLC45A4 HUMAN 57210 
62 NM_181785 SLC46A3 HUMAN 283537 
63 NM_022551 RPS18 HUMAN 6222 
64 NM_000942 PPIB HUMAN 5479 
65 NM_003194 TBP HUMAN 6908 
66 NM_000181 GUSB HUMAN 2990 
67 NM_000698 ALOX5 HUMAN 240 
68 NM_001629 ALOX5AP HUMAN 241 
69 NM_000895 LTA4H HUMAN 4048 
70 NM_145867 LTC4S HUMAN 4056 
71 NM_000963 PTGS2 HUMAN 5743 
72 NM_001061 TBXAS1 HUMAN 6916 
73 NM_181657 LTB4R HUMAN 1241 
74 NM_019839 LTB4R2 HUMAN 56413 
75 NM_006639 CYSLTR1 HUMAN 10800 
76 NM_020377 CYSLTR2 HUMAN 57105 
77 NM_001060 TBXA2R HUMAN 6915 
78 NM_006793 PRDX3 HUMAN 10935 
79 NM_001512 GSTA4 HUMAN 2941 
80 NM_012239 SIRT3 HUMAN 23410 
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Supplemental Table S2. PCR primers. 
 
Gene Mouse Accession 
# 
Primer Primer-Sequence 
ABCD4 NM_008992 Forward primer GTTCCTGCCTCAGAAGCCAT 
  Reverse primer CAATCCTCTCATCGTCCGCA 
ATGL AK 031609 Forward primer AACACCAGCATCCAGTTCAA 
  Reverse primer GGTTCAGTAGGCCATTCCTC 
CD36 NM_001159555.1 Forward primer CTTCACCAGAAATAGACCCTTGT 
  Reverse primer CAGATGCTAATTTGTGGTTGGTTG 
CGI58 NM_026179 Forward primer TCCTACCTGGTGTCCCACAT 
  Reverse primer GGATATGCGCACAGGCTCTT 
FABP4 NM_024406.3  Forward primer GCGTGGAATTCGATGAAATCA 
  Reverse primer CCCGCCATCTAGGGTTATGA 
FATP1 XM_006509678.3  Forward primer TTGCCCACAGCGTTTTCC 
  Reverse primer CACTAGCACGTCACCTGAGAGGTA 
G0S2 NM_008059.3 Forward primer GCGGATCCCGGACAAAAGAT 
  Reverse primer ACTGGCTTTGGCGTTCTTCT 
HSL NM_001039507 Forward primer TCATGGCTCAACTCCTTCCT 
  Reverse primer CTGCCTCAGACACACTCCTG 
SLC16A6 NM_134038 Forward primer GTTTCCTCCCAACTGTGACCA 
  Reverse primer TAGCTGGTGCGAAAGCAAAC 
SLC22A1
5 
NM_001039371 Forward primer GGGGCAGCATTTATGCCAAC 
  Reverse primer AGAAACGCTGCTAGTGTCCG 
SLC25A3
3 
NM_027460 Forward primer AGACTAGCTCTTCGGACGGT 
  Reverse primer CGTCACAGACGTTGGTCTCA 
SLC35C
2 
NM_001252575 Forward primer GATTCTGGCCTTCGGTTTGG 
  Reverse primer GATGCCAGCGATGGAGAGTG 
SLC43A3 NM_021398 Forward primer CACGTGGTGTGGCTGTCTAT 
  Reverse primer GTCCCCACCGGATAACTTGG 
Plin1 NM_175640.2 Forward primer CATCTCTACCCGCCTTCGAA 
  Reverse primer TGCTTGCAATGGGCACACT 
SR-B1 XM_017320764.1  Forward primer TCCCTTCGTGCATTTTCTCA 
  Reverse primer GTTCATCCCAACAAACAGGC 
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A1 Zusammenfassung 
 
Adipozyten sind Zellen mit endokriner Funktion, die aktiv freie Fettsäuren 
aufnehmen und unter unterschiedlichen physiologischen Konditionen freigeben. 
Sie sind an der Regulation des Fettstoffwechsels beteiligt und somit Teil des 
Energiestoffwechsels. Eine Fehlregulation dieser Lipidhomöostase ist ein 
wesentlicher Faktor für das Entstehen von Erkrankungen wie Diabetes, 
kardiovaskulärer Herzkrankheit (KHK) und nicht-alkoholischer Fettleber 
(NAFLD, „nonalcoholic fatty liver disease“). 
Freie Fettsäuren werden entweder in Form von Triglyceriden in Adipozyten 
gespeichert oder bewegen sich frei im Plasma. Die meisten Zellen, außer 
Adipozyten, haben keine ausreichende Kapazität um freie Fettsäuren zu 
speichern und sind deshalb auf die frei-zirkulierenden Fettsäuren angewiesen. 
Der Transport von freien Fettsäuren über die Plasmamembran wird von einer 
umfangreichen Menge an Proteinen und Enzymen kontrolliert und unterliegt 
verschschiedensten metabolischen und hormonellen Faktoren. Die Aufnahme 
von freien Fettsäuren scheint nicht durch Diffusion, sondern durch spezielle 
Transporter, welche an der Plasmamembran lokalisiert sind, zu erfolgen. 
Verschiedene Studien zur Aufnahme von freien Fettsäuren zeigten, dass 
Transportproteine wie Fettsäuretransporter (FATP), Thrombozytenglykoprotein 
4 (FAT/CD36) und Fettsäure-CoA-Liagesen (ACSL), eine wesentliche Rolle in 
diesem Transportprozess übernehmen. 
Obwohl heutige Arbeiten die diffusions-vermittelte Aufnahme freier Fettsäuren 
widerlegen, ist man immernoch der Annahme, dass die Freisetzung von freien 
Fettsäuren nach diesem Mechanismus erfolgt. Henkin et al. präsentierten 
jedoch Daten, die eine mögliche Beteiligung von speziellen Transportproteinen 
an dieser Freisetzung, suggerieren. Obwohl das Thema „Transport von freien 
Fettsäuren“ immer wieder erforscht und diskutiert wird, sind die exakten 
Mechanismen dieses Vorgangs noch nicht vollständig geklärt. Sind spezielle 
Membranporteine an der Abgabe freier Fettsäuren aus dem Adipozten 
beteiligt? Werden bereits erforschte Membrantransporter, wie FATP, CD36 oder 
ACSL, von bislang unbekannten Proteinen beeinflusst?  
Der Versuch diese Fragen zu beantworten, begann mit einer in-silico Suche 
nach Proteinen mit folgenden Merkmalen: bislang keine gesicherte Funktion, 
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auf der Plasmamembran lokalisiert, ausreichende Expression im adipösen 
Gewebe. 
Die Veränderung der Expression dieser Proteine wurde dann in Patienten vor- 
und nach bariatrischer Chirurgie untersucht. Mehr als 20 dieser Proteine 
zeigten eine signifikante Veränderung ihrer Expression (prä-operativ vs. post-
operativ). Dieser Umstand macht es denkbar, dass die untersuchten Proteine 
eine Rolle im Fettstoffwechsel spielen könnten.  
Zum Fokus dieser Studie wurde das Protein Slc43a3. Es zeigte eine hohe 
Expression in verschiedenen adipösen Geweben, welche vergleichbar mit 
bereits bekannten Fettstoffwechsel-Proteinen, wie Plin1, Hsl und Fabp4 ist. 
Außerdem zeigte sich eine vermehrte Expression von Slc43a3 im Verlauf der 
Zelldifferenzierung von Präadipozyten zu Adipozyten in in-vitro Experimenten 
mit Zellen der murinen OP9-Zelllinie und Präadipozyten, die aus Mäusen 
gewonnen wurden. 
Besonders beeindruckend war jedoch der Effekt von Slc43a3 auf die 
Fettsäureaufnahme und Fettsäurefreisetzung. Zellen, in denen künstlich mit si-
Slc43a3/ Slc4a3-clone das Protein Slc43a3 herunterreguliert bzw. 
überexprimiert wurde, zeigten signifikante Unterschiede in der Aufnahme und 
bei der Abgabe von freien Fettsäuren. Bei einer Überexprimierung von Slc43a3 
nahm die Aufnahme von freien Fettsäuren und die Anhäufung von Lipidtropfen 
signifikant ab (P<0.001). Wohingegen bei einer Herunterregulierung von 
Slc43a3 die Aufnahme von freien Fettsäuren und die Anhäufung von 
Lipidtropfen signifikant zunahm (P<0.001). Auch die Freisetzung von freien 
Fettsäuren scheint durch eine Herunterregulierung von Slc43a3 beeinflusst zu 
werden, denn dessen Rate nimmt zum einen im Vergleich zur Kontrolle unter 
normalen Konditionen (P<0.05), als auch in Forskolin-stimulierten Zellen, 
signifikant ab (P<0.01).  
Auf der Suche nach Mechanismen für diese Beobachtungen, wurden 
verschiedene experimentelle Ansätze verfolgt. Zunächst wurde untersucht ob 
die Herunter-/ Hochregulierung von Slc43a3 die Spiegel von cyclischem 
Adenosinmonophosphat (cAMP) beinflusst. Tatsächlich zeigten sich signifikante 
Unterschiede zwischen transfizierten Zellen im Vergleich zur Kontrolle. Da 
jedoch sowohl die Herunterregulierung als auch die Überexpression von 
Slc43a3 die Forskolin-stimulierten cAMP Spiegel senkten, scheint der Effekt 
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von Slc43a3 unabhängig von der Produkution von cAMP zu sein.  
Desweiteren wurde untersucht ob Slc43a3 eventuell zusammen mit anderen 
Fettstoffwechsel-Proteinen agiert oder diese beeinflusst. Aber sowohl eine 
Herunterregulierung als auch eine Überexpression zeigten keine signifikaten 
Unterschiede in der Expression von Proteinen wie SR-B1, CD36, HSL, ATGL, 
CGI58, G0S2, FATP1 oder Plin1. 
Zuletzt wurde eine mögliche Beziehung von Slc43a3 zu CD36 geprüft. Ein 
Experiment zur Aufnahme freier Fettsäuren wurde in si-Slc43a3, si-CD36 und 
si-Slc43a3+CD36 transfizierten Zellen durchgeführt. Das Resultat dieses 
Experiments macht es jedoch wahrscheinlich, dass Slc43a3 den 
Fettstoffwechsel unabhängig von CD36 beeinflusst. 
Unabhängig vom genauen Aktionsmechanismus lässt sich zusammenfassen, 
dass Slc43a3 den Transport freier Fettsäuren in Adipozyten (mit-) reguliert. 
Slc43a3 funktioniert als positiver Regulator bei der Freisetzung von freien 
Fettsäuren und als negativer Regulator bei der Aufnahme von freien 
Fettsäuren. Der genaue molekulare Mechanismus bleibt dabei unklar und ist 
Gegenstand weiterer Forschungsarbeiten.  
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A3 List of abbreviations 
 
ABC ATP-binding cassette 
ACSL long chain fatty acyl coenzyme A synthetase 
Amp ampicillin 
AUC area under the curve 
bDNA branched DNA 
BMI  body mass index 
BSA bovine serumalbumin 
cAMP cyclic adenosine monophosphate  
EEG1 embryonic epithelia gene 1 
FA(s) fatty acid(s) 
FAT fatty acid translocase (CD36) 
FATP fatty acid transport protein 
FABP fatty acid binding protein 
FFA(s) free fatty acid(s) 
GI gastrointestinal (tract) 
h hour(s) 
HDL high-density lipoprotein 
HSL hormone-sensitive lipase 
IDL intermediate-density lipoprotein 
IL interleukin 
KO knockout 
LAT amino acid system L transporter 
LB lysogeny broth  
LCFA(s) long chain fatty acid(s) 
LDL low-density lipoprotein 
min minute(s) 
PBS phosphate-buffered saline 
PBST phosphate-buffered saline with Tween 20 
PLIN1 lipid droplet-associated protein (Perilipin-1) 
PM plasma membrane 
PPAR peroxisome proliferator activated receptor 
 x  
RFU relative fluorescence units 
rpm rounds per minute 
s second(s) 
SLC solute carrier 
TAG triacylglycerol 
TNF tumor necrosis factor 
VLDL very-low-density lipoprotein 
VSG vertical sleeve gastrectomy 
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